Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 384

1.

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D.

Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.

2.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574. [Epub ahead of print]

PMID:
29965787
3.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5.

PMID:
29958569
4.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Jun 28. pii: haematol.2017.185991. doi: 10.3324/haematol.2017.185991. [Epub ahead of print]

5.

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R.

Cancer Med. 2018 Jun 21. doi: 10.1002/cam4.1620. [Epub ahead of print]

6.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 May 28. pii: S2152-2650(18)30338-0. doi: 10.1016/j.clml.2018.05.019. [Epub ahead of print]

PMID:
29910180
7.

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.

Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17.

PMID:
29793653
8.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 May 2. doi: 10.1038/s41375-018-0040-1. [Epub ahead of print] Review.

9.

The start of a new wave: Developments in proteasome inhibition in multiple myeloma.

Yong K, Gonzalez-McQuire S, Szabo Z, Schoen P, Hajek R.

Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13071. [Epub ahead of print] Review.

PMID:
29603798
10.

Venetoclax: A new wave in hematooncology.

Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R.

Exp Hematol. 2018 May;61:10-25. doi: 10.1016/j.exphem.2018.02.002. Epub 2018 Mar 2. Review.

PMID:
29477371
11.

Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing.

Chyra Kufova Z, Sevcikova T, Januska J, Vojta P, Boday A, Vanickova P, Filipova J, Growkova K, Jelinek T, Hajduch M, Hajek R.

J Clin Pathol. 2018 Feb 17. pii: jclinpath-2017-204978. doi: 10.1136/jclinpath-2017-204978. [Epub ahead of print]

12.

Current applications of multiparameter flow cytometry in plasma cell disorders.

Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Paiva B, Hajek R.

Blood Cancer J. 2018 Jan 19;8(1):e621. doi: 10.1038/bcj.2017.101.

13.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ.

Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7.

PMID:
29315478
14.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

15.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P.

Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review.

16.

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

Jelínek T, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Adamová D, Wróbel M, Mikula P, Jarkovský J, Diels J, Gatopoulou X, Veselá Š, Besson H, Brožová L, Ito T, Hájek R.

Curr Med Res Opin. 2018 May;34(5):775-783. doi: 10.1080/03007995.2017.1410121. Epub 2018 Feb 15.

PMID:
29172760
17.

Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry Characterization of Gangliosides in Biological Samples.

Hájek R, Jirásko R, Lísa M, Cífková E, Holčapek M.

Anal Chem. 2017 Nov 21;89(22):12425-12432. doi: 10.1021/acs.analchem.7b03523. Epub 2017 Nov 3.

PMID:
29058414
18.

Current applications of multiparameter flow cytometry in plasma cell disorders.

Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Paiva B, Hajek R.

Blood Cancer J. 2017 Oct 20;7(10):e617. doi: 10.1038/bcj.2017.90. Review. Erratum in: Blood Cancer J. 2018 Jan 19;8(1):e621.

19.

A Lifestyle Intervention via Email in Minority Breast Cancer Survivors: Randomized Parallel-Group Feasibility Study.

Paxton RJ, Hajek R, Newcomb P, Dobhal M, Borra S, Taylor WC, Parra-Medina D, Chang S, Courneya KS, Block G, Block T, Jones LA.

JMIR Cancer. 2017 Sep 21;3(2):e13. doi: 10.2196/cancer.7495.

20.

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma.

Steiner N, Borjan B, Hajek R, Jöhrer K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G.

Oncotarget. 2017 Apr 21;8(34):56243-56254. doi: 10.18632/oncotarget.17353. eCollection 2017 Aug 22.

21.

Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.

Growkova K, Kufová Z, Sevcikova T, Filipová J, Kascak M, Jelínek T, Grosicki S, Barchnicka A, Roziaková Ľ, Mistrík M, Simicek M, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):81-91. doi: 10.14735/amko20172S81.

PMID:
28903575
22.

Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease.

Zatopkova M, Filipová J, Jelínek T, Vojta P, Sevcikova T, Simicek M, Rihova L, Bezdekova R, Growkova K, Kufová Z, Smejkalová J, Hajdúch M, Pour L, Minárik J, Jungová A, Maisnar V, Kryukov F, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):75-80. doi: 10.14735/amko20172S75.

PMID:
28903574
23.

CRISPR in Research and Treatment of Multiple Myeloma.

M Simicek M, Growkova K, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):68-74. doi: 10.14735/amko20172S68.

PMID:
28903573
24.

Biomarkers in Immunoglobulin Light Chain Amyloidosis.

Kufová Z, Sevcikova T, Growkova K, Vojta P, Filipová J, Adam Z, Pour L, Penka M, Rysava R, Němec P, Brozova L, Vychytilova P, Jurczyszyn A, Grosicki S, Barchnicka A, Hajdúch M, Simicek M, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):60-67. doi: 10.14735/amko20172S60.

PMID:
28903572
25.

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.

Brozova L, Jarkovský J, Pour L, Minárik J, Jungová A, Gregora E, Spicka I, Maisnar V, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):51-59. doi: doi: 10.14735/amko20172S51.

PMID:
28903571
26.

Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.

Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, Jarkovský J, Němec P, Horinek D, Stefanikova Z, Pour L, Hájek R, Maisnar V.

Klin Onkol. 2017 Summer;30(Supplementum2):43-50. doi: 10.14735/amko20172S43.

PMID:
28903570
27.

Epidemiology of Multiple Myeloma in the Czech Republic.

Maluskova D, Svobodová I, Kucerova M, Brozova L, Muzik J, Jarkovský J, Hájek R, Maisnar V, Dusek L.

Klin Onkol. 2017 Summer;30(Supplementum2):35-42. doi: 10.14735/amko20172S35.

PMID:
28903569
28.

Circulating Plasma Cells in Monoclonal Gammopathies.

Bezdekova R, Penka M, Hájek R, Rihova L.

Klin Onkol. 2017 Summer;30(Supplementum2):29-34. doi: 10.14735/amko20172S29.

PMID:
28903568
29.

Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.

Rihova L, Vsianska P, Bezdekova R, Kralova R, Penka M, Krejci M, Pour L, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):21-28. doi: 10.14735/amko20172S21.

PMID:
28903567
30.

Biobanking - the First Step to Successful Liquid Biopsy Experiments.

Almasi M, Sevcikova S, Penka M, Krejci M, Adam Z, Vrublova P, Jelínek T, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):9-12. doi: 10.14735/amko20172S9.

PMID:
28903566
31.

Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection.

Growková K, Kryukova E, Kufová Z, Filipová J, Ševčíková T, Říhová L, Kaščák M, Kryukov F, Hájek R.

Eur J Haematol. 2017 Dec;99(6):469-478. doi: 10.1111/ejh.12959. Epub 2017 Oct 10. Review.

PMID:
28886236
32.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.

PMID:
28843768
33.

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.

Steiner N, Hajek R, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Untergasser G, Gunsilius E.

PLoS One. 2017 Jul 20;12(7):e0181487. doi: 10.1371/journal.pone.0181487. eCollection 2017.

34.

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R.

Immunology. 2017 Nov;152(3):357-371. doi: 10.1111/imm.12788. Epub 2017 Aug 4. Review.

PMID:
28685821
35.

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA.

Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.

36.

Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.

Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, Bezdekova R, Stork M, Adam Z, Pour L, Krejci M, Kuglík P, Hajek R, Sevcikova S.

Eur J Haematol. 2017 Sep;99(3):223-233. doi: 10.1111/ejh.12908. Epub 2017 Jun 29.

PMID:
28543758
37.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG.

Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.

38.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096. No abstract available.

PMID:
28453614
39.

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H.

Leukemia. 2017 Dec;31(12):2630-2641. doi: 10.1038/leu.2017.122. Epub 2017 Apr 25.

40.

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.

Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A.

Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.

41.

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.

Sandecká V, Hájek R, Pour L, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, Zahradová L, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, Wróbel M, Brožová L, Jarkovský J, Mikulášová A, Říhová L, Ševčíková S, Straub J, Minařík J, Adam Z, Krejčí M, Král Z, Maisnar V; Czech Myeloma Group.

Eur J Haematol. 2017 Jul;99(1):80-90. doi: 10.1111/ejh.12894. Epub 2017 May 11.

PMID:
28384387
42.

IgM myeloma: A multicenter retrospective study of 134 patients.

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA.

Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

PMID:
28383205
43.

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E.

Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6.

PMID:
28382618
44.

Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).

Thomsen H, Campo C, Weinhold N, da Silva Filho MI, Pour L, Gregora E, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Goldschmidt H, Hemminki K, Försti A.

Eur J Haematol. 2017 Jul;99(1):70-79. doi: 10.1111/ejh.12892. Epub 2017 May 24.

PMID:
28375557
45.

Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies.

Ševčíková T, Growková K, Kufová Z, Filipová J, Vrublová P, Jelínek T, Kořístek Z, Kryukov F, Kryukova E, Hájek R.

J Clin Pathol. 2017 Oct;70(10):847-853. doi: 10.1136/jclinpath-2017-204329. Epub 2017 Mar 30.

46.

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D.

Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17. No abstract available.

PMID:
28306371
47.

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.

Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P.

Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17.

48.

[Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories].

Jelínek T, Kořístka M, Čermáková Z, Hájek R.

Klin Onkol. Winter 2017;30(1):13-19. doi: 10.14735/amko201713. Review. Czech.

PMID:
28185460
49.

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.

Jelinek T, Hajek R.

Oncoimmunology. 2016 Nov 8;5(12):e1254856. doi: 10.1080/2162402X.2016.1254856. eCollection 2016. Review.

50.

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.

Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A.

Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272684. Epub 2017 Jan 16.

PMID:
28092996

Supplemental Content

Support Center